Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab in Allergic Fungal Rhinosinusitis (AIMS)
NCT04684524Phase 3Completed
- Sponsor
- Sanofi
- Start
- Dec 2020
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies
- Countries
- 9
01
Overview
A Phase 3 trial of dupilumab in allergic fungal rhinosinusitis (AFRS), sponsored by Sanofi. Started Dec 2020; status: completed.
02
Drugs
03
Conditions
allergic fungal rhinosinusitis (AFRS)
Beyond the preview
Go deeper on NCT04684524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04684524.